We previously established a method to generate myeloid cells with a proliferative capability from pluripotent stem cells and designated them iPS-ML. Human iPS-ML cells share features with physiological macrophages including the capability to infiltrate into cancer tissues. We observed therapeutic effects of human iPS-ML cells expressing interferon β (iPS-ML/interferon (IFN)-β) in xenograft cancer models.
| INTRODUC TI ON
Interferon (IFN)-α, -β, and -γ exert direct anticancer effects via growth inhibition or death induction of cancer cells. [1] [2] [3] [4] [5] [6] [7] In addition, activation of immune cells and inhibition of cancer angiogenesis by IFNs is known. [8] [9] [10] [11] However, the clinical use of IFNs as anticancer agents is limited. The restricted clinical merit of IFNs is due to their rapid inactivation and inefficient tissue penetration after intravenous injection. 12 In addition, systemic toxicity precludes high-dose intravenous administration. [13] [14] [15] [16] Drug delivery systems (DDSs) that make IFNs act specifically on cancer tissues may significantly improve the therapeutic benefits of IFNs.
Infiltration of macrophages is observed in various cancer tissues. [17] [18] [19] [20] [21] [22] [23] [24] This infiltration depends on their expression of receptors for many kinds of leukocyte-attracting factors such as chemokines, complement proteins, and various damage-associated molecular pattern molecules (DAMPs). 25, 26 We hypothesized that macrophages producing IFNs may be useful as DDS for cancer therapy.
We previously established a method to induce the proliferation of human induced pluripotent stem (iPS) cell-derived myeloid cells to generate iPS cell-derived myeloid/macrophage cell lines (iPS-ML). [27] [28] [29] Similar to physiological macrophages, iPS-ML cells expressed various receptors related to tissue infiltration. When human iPS-ML cells were injected into severe combined immunodeficiency (SCID) mice bearing cancers (xenograft cancer models), iPS-ML cells accumulated and infiltrated into the cancer tissues, indicating a cancerdirected migration capacity of iPS-ML. iPS-ML transduced with an expression vector for IFN-β (iPS-ML/IFN-β) exhibited a therapeutic effect in several xenograft cancer models. 30, 31 However, from experiments with xenograft cancer models, we could not evaluate the indirect therapeutic effects of iPS-ML/IFN mediated by the host immune system. In addition, IFN toxicity could not be assessed by xenograft experiments because of the species differences in IFN-β and IFN-γ between humans and mice. To examine both the beneficial and adverse effects of iPS-ML/IFN therapy, experiments using syngeneic cancer models with immunocompetent mice must be necessary. Because a iPS-ML/IFN derived from mouse iPS cells has not yet been developed in our laboratory, in the current study we utilized 129Sv mouse ES cell-derived myeloid cell lines producing IFNs (ES-ML/IFN) as donor cells to treat mice in an allogeneic and cancer-bearing mouse model, assuming the therapy with human iPS-ML/IFN cells. In the current study, we disrupted the genes encoding H-2K b , D b , and I-Aβ b molecules in the 129Sv mouse (H-2 b )-derived ES-ML/IFN using the clustered regularly interspaced short palindromic repeats (CRISPR) method. We transferred these cells into cancer-bearing allogeneic BALB/c mice (H-2 d ) to investigate whether the MHC-deficient ES-ML/IFN can be used for cancer therapy in MHC-mismatched recipients.
iPS-ML cells can be expanded using a simple suspension culture procedure, and an automated cell culture system is applicable to provide sufficient quantities of cells required for clinical use. We presumed that we could use human leukocyte antigen (HLA)-A/B/ DR-deficient iPS-ML/IFN cells for treatment of any cancer patient irrespective of their HLA type, by avoiding acute rejection. If this concept is proven, mass production of cellular pharmaceuticals for anticancer therapy can be realized.
| MATERIAL S AND ME THODS

| Cell lines
Colon26, colon cancer cells, BALB-MC, breast cancer cells, and SP2/0, myeloma cells derived from the BALB/c mouse strain were provided from RIKEN, JCRB Cell Bank, and the European Collection of Authenticated Cell Cultures (ECACC), respectively.
| Generation of mouse ES cell-derived myeloid cells producing IFNs
E14 ES cells derived from the 129Sv mouse strain were seeded onto a feeder cell layer of OP9 mouse bone marrow stromal cells. On d 5 or 6, cells were harvested, reseeded onto fresh OP9 cell layers, and cultured in the presence of granulocyte-macrophage colony stimulating factor (GM-CSF) (1000 U/mL). On d 13 and 14, myeloid lineage cells were recovered, 32 and transduced with a lentiviral expression vector CSIIEF 33 for cMYC to establish the ES-ML line. 34 Subsequently, ES-ML cells were transduced with expression vectors for mouse GM-CSF and M-CSF. To generate ES-ML lines producing high amounts of IFNs, genes encoding for the components of type I and type II IFN receptors were disrupted using zinc finger nucleases (Sigma CKOZFND33655 for ifnar2 and CKOZFND33659 for ifngr1) before introduction of expression vectors for mouse IFN-β and IFN-γ, respectively.
| Disruption of genes encoding for H-2K, D, and I-Aβ in the ES-ML/IFN
The E14 ES cell-derived ES-ML/IFN were transduced with a CAS9 nuclease expression vector together with guide RNA (gRNA) expression vectors by lentivirus vectors. The target sequence of gRNA 
| Analysis of sensitivity of Colon26 cells to IFN-β and IFN-γ
Colon26 cells expressing firefly luciferase (Colon26/Luc) 34 were cultured in the presence of recombinant mouse (rm) IFN-β (10 ng/ mL) and/or rmIFN-γ (10 ng/mL). After 3 d, luciferase substrate (Steadylite plus, Perkin-Elmer) was added, and luminescence activity was quantified using a microplate reader (TriStar; Berthold Technologies). To detect apoptosis, the cells were stained with annexin V-fluorescein isothiocyanate (FITC). To assess live cells based on nicotinamide adenine dinucleotide (NADH) quantification using the water-soluble disulfonated tetrazolium salt, the Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies) was used. To analyze proliferative activity, cells were centrifuged at 270 g for 6 min, fixed with cold 70% ethanol, incubated for 1 h at −20°C, and stained with an anti-Ki67 antibody (clone REA183;
Miltenyi Biotec). 
| Analysis of in vivo anticancer effects of the ES-ML/IFN
| Analysis of ES-ML/IFN infiltration into cancer tissues
Green fluorescent protein (GFP)-expressing Colon26 cells (Colon26/ GFP, 2 × 10 6 cells/mouse) were injected ip into mice. After 3 d, β-ML (1.6 × 10 7 ) and γ-ML cells (4 × 10 6 ) were labeled with a red fluorescent linker PKH26 (Sigma) and injected ip. The next day, mice were euthanized, and the locations of Colon26/GFP cells and the PKH26-labeled ES-ML/IFN were detected macroscopically by fluorescence at excitation wavelengths of 475 and 500 nm and emission filters of 520 and 600 nm, respectively, using the NightOWL II.
For microscopic examination, β-ML and γ-ML labeled with PKH26 were injected ip at 10 d after inoculation of Colon26/GFP cells. The next day, cancer tissues were isolated, fixed in 4% paraformaldehyde/phosphate-buffered saline, and embedded in Tissue-TEK OCT (Sakura Fine Technical). Tissue sections of 4-6-μm thickness were prepared using a cryostat and analyzed by fluorescence microscopy (Axio Observer Z1; Carl Zeiss).
| Analysis of CD4 + cells and CD8 + cells infiltration into cancer tissues
Cancer nodules on the mesentery were resected from mice and frozen sections (4-μm thickness) were prepared, fixed with cold acetone, incubated with 1% bovine serum albumin/TBS-T with NaN 3 for blocking, and stained with anti-CD4 (GK1.5) and anti-CD8 (53-6.72) monoclonal antibodies. The sections were treated with a horseradish peroxidase-conjugated anti-rat secondary antibody (Nichirei).
Diaminobenzidine (DAB; Nichirei) was used to visualize antibody reactions. Nuclei were counterstained with hematoxylin.
| Flow cytometric analysis
The following monoclonal antibodies were used: FcR-blocking anti- 
| Life span of β-ML in peritoneal dissemination model
| Evaluation of the anticancer effect of CD8 + T cells in vitro
Colon26/Luc cells (4 × 10 6 cells/mouse) were injected ip to establish a peritoneal dissemination model. Mice were divided into treatment (administration of both β-ML and γ-ML) and control (no treatment) groups. Treatment group mice were administrated twice from d 4 with a mixture of β-ML and γ-ML. CD8 + T cells were isolated from mesenteric lymph nodes (MLNs) and para-aortic lymph nodes (PANs) using magnetic beads (CD8 MicroBeads for mouse; Miltenyi Biotec). The CD8 + T cells (1 × 10 4 cells/well) were cultured with Colon26/Luc cells (5 × 10 3 cells/well). Luciferase substrate solution was added (50 μL/well) after 3 d of culture, and luminescence was measured. 
| Enzyme-linked ImmunoSpot (ELISPOT) analysis of IFN-γ production
IFN-γ-producing cells in natural killer (NK) cells isolated with an NK
Cell Isolation Kit II (Miltenyi Biotec) were also analyzed by ELISPOT assay using syngeneic SP2/0 cells as NK target cells.
| Depletion of CD4 + and CD8 + T cells in vivo
InVivoMab anti-mouse CD4 (clone GK1.5; Bio X Cell) and IgG from rat serum (Sigma) were used as an isotype-matched control antibody. To prepare the anti-CD8 monoclonal antibody, hybridoma cells (clone 3.155; 1 × 10 6 /mouse) were injected ip into ICR nude mice and ascites were harvested. Ascites were treated with Ascites Conditioning Reagent (Thermo Scientific), desalted with a Scientific™ Zeba™ Spin Desalting Colum (Thermo Scientific), and purified using a Melon Gel IgG Purification Kit (Thermo Scientific). In T cell-depletion experiments, Colon26/Luc cells (1 × 10 6 cells/mouse) were injected ip into mice at d 0. Each antibody (50 μg/mouse) was injected ip at d −3, −1, and 6, and depletion of CD4 + and CD8 + T cells was checked by flow cytometry at d 3 and d 6 in blood samples. A P-value < .05 was considered as significant. The log-rank test was used to analyze mouse survival using GraphPad Prism software. A P-value < .05 was considered as significant.
| Statistical analysis
| RE SULTS
| Pro-apoptotic and growth-inhibitory effects of rmIFN-β and rmIFN-γ on Colon26 cells
We 
| Disruption of the genes encoding for H-2K, D, and I-Aβ molecules in the ES-ML/IFN
We disrupted the genes encoding H-2K b , D b , and I-Aβ b molecules in the ES-ML/IFN. We transduced β-ML with a mixture of lentiviral gRNA expression vectors along with a CAS9 nuclease expression vector. Subsequently, cells deficient in the expression of H-2K, D, and I-A were purified using anti-MHC antibodies and magnetic beads. The absence of these MHC molecules in the resulting cells was verified by flow cytometric analysis ( Figure S2 ).
We also established MHC-deficient γ-ML cells using the same methods (data not shown). In all of the following in vivo experiments, the MHC-deficient ES-ML/IFN were transferred into allogeneic and cancer-bearing BALB/c mice (H-2 d ) for evaluation of their therapeutic effects.
| Therapeutic effect of ES-ML/IFN against peritoneally disseminated colon cancer
To evaluate the anticancer therapeutic effect of the ES-ML/IFN, we injected ip the ES-ML/IFN into cancer-bearing mice. The half-life of β-ML administrated into the peritoneal cavity of the allogeneic and cancerbearing BALB/c mice is estimated to be c. 28 h ( Figure S3 ), therefore the ES-ML/IFN was administrated twice a week for 2-4 wk to obtain anticancer effects. We determined 3 × 10 6 and 7.5 × 10 5 cells per injection per mouse as the tolerated doses of β-ML and γ-ML, respectively, because repetitive injections of these numbers of the ES-ML/IFN did not cause apparent adverse effects in the mice even if β-ML and γ-ML were simultaneously injected.
To establish a model of peritoneal dissemination of colon cancer, we injected ip Colon26/Luc cells and monitored cancer growth by bioluminescence analysis. Mice engrafted with Colon26/Luc cells on d 2 were divided into therapy and no therapy (control) groups. Mice in the therapy group were treated by injection ip of β-ML twice a week for 4 wk from d 2. Cancer growth was inhibited by treatment with β-ML (Figure 2A,B ). In addition, survival of the cancer-bearing mice was extended by the therapy (Figure 2C) , suggesting that the therapeutic benefit of the administration of β-ML surpassed the harmful effects.
| Therapeutic effect of the ES-ML/IFN against colon cancer injected into liver
We injected Colon26/Luc cells into the left lobe of mouse liver. After 4 d, colonization of cancer cells was verified by an in vivo bioluminescence assay, and cancer-positive mice were divided into control and treatment groups. Therapy with β-ML inhibited cancer growth ( Figure 3A,B) and extended the survival of mice ( Figure 3C ). Conversely, therapy with γ-ML was not effective ( Figure S4 ). Simultaneous injections of β-ML and γ-ML were also effective ( Figure S5 ). F I G U R E 2 Therapeutic effect of β-ML against peritoneally disseminated colon cancer. Colon26/Luc cells were injected ip. The mice were divided into no therapy (n = 7) and β-ML therapy (n = 9) groups. The mice in the β-ML therapy group were injected ip with β-ML (3 × 10 6 ) from d 2, twice each week for 4 wk. A, Luminescence images are shown. B, Cancer growth of the two groups is indicated as the fold change of luminescence counts in comparison with counts observed on d 2. The linear mixed model was performed to compare the data of the no therapy and β-ML groups, and the difference between the two groups is statistically significant (*P < .05). C, Kaplan-Meier survival curves for β-ML-treated and no therapy groups are shown. The difference between the two groups is statistically significant (**P < .01, log-rank test)
| Infiltration of the ES-ML/IFN into cancer tissues
We next examined infiltration of β-ML and γ-ML into cancer tissues. F I G U R E 3 Therapeutic effect of β-ML against colon cancer in liver. Colon26/ Luc cells (5 × 10 5 /mouse) were inoculated into the left liver lobe on d 0. On d 4, mice were divided into no therapy (n = 10) and β-ML therapy (n = 10) groups. The mice in the therapy group were injected ip with β-ML (3 × 10 6 ) from d 4, twice each week for 4 wk. A, Luminescence images of the mice are shown. B, Cancer growth is indicated as the fold change of luminescence counts in comparison with counts observed on d 4. The mean ± SD of the mouse groups are shown. The difference between the two groups was statistically significant (**P < .01, linear mixed model). C, Kaplan-Meier survival curves are shown. The difference between the two groups was statistically significant (*P < .05, log-rank test) F I G U R E 4 Enhanced infiltration of CD4 + cells and CD8 + cells into cancer tissues in mice treated with the ES-ML/IFN. Colon26 cells (4 × 10 6 /mouse) were injected ip into BALB/c mice. Mice were treated from d 4, twice each week for 2 wk with both β-ML (3 × 10 6 ) and γ-ML (7.5 × 10 5 ) (n = 9) or untreated (n = 9). Then, peritoneal cancer tissues were resected and subjected to immunohistochemical analyses. A, Tissue sections were stained with anti-CD4 and anti-CD8 antibodies, and reactions were visualized with DAB. Scale bars represent 50 μm. B, The numbers of CD4 + cells and CD8 + cells in the cancer tissues were significantly increased in the treated mice in comparison with mice without treatment. The difference between values from the no therapy and therapy groups was evaluated using Student's t test (**P < .01) For microscopic analysis, PKH26-labeled β-ML and γ-ML were injected at 10 d after injection of cancer cells. The next day, cancer nodules were isolated, and frozen sections were prepared.
Histological analysis indicated infiltration of the ES-ML/IFN into the cancer capsule and inside cancer tissues ( Figure S6C,D) .
| Enhanced infiltration of CD4 + and CD8 + cells into cancer tissues by treatment with the ES-ML/IFN
We examined cancer-infiltrating cells by immunohistochemical analysis. Colon26/Luc cells were injected ip, and mice were treated with β-ML and γ-ML twice a week for 2 wk. Then, we isolated peritoneal cancer tissues and subjected them to immunostaining to detect CD4 + cells and CD8 + cells. Higher numbers of both CD4 + cells and CD8 + cells were observed in cancer tissues of treated mice in comparison with those of untreated mice ( Figure 4A,B ).
| Increased numbers of immune cells in the spleen and lymph nodes of the ES-ML/IFN-treated cancer-bearing mice
Next, we analyzed the influence of ES-ML/IFN treatment on the number of immune cells in the lymphoid organs. Peritoneal cancerbearing mice were injected with β-ML and γ-ML twice a week and sacrificed after four times injection, and the numbers of immune cells in the lymph nodes and spleen were examined.
The total cell number of spleen and PANs was increased by the treatment (Figure 5 ). In spleen, NK cells, myeloid cells, and CD4 + cells were increased, while Th1 cells (CD4 + and IFN-γ + ), CD8 + cells, and effector CD8 + T cells (CD8 + and IFN-γ + ) were not increased.
Conversely, all these subpopulations were increased in PANs, and the magnitude of increase of the cell numbers was much higher in PANs than in the spleen. ES-ML/IFN treatment also increased the numbers of CD4 + cells and CD8 + cells in both mesenteric (draining) and inguinal (non-draining) lymph nodes ( Figure S7 ). The magnitude of increase of T cells in the draining lymph nodes was higher than those in the non-draining lymph nodes. Collectively, injection ip of the ES-ML/IFN into cancer-bearing mice increased immune cells in lymphoid organs, and the increase was more marked in draining lymph nodes than in spleen or non-draining lymph nodes.
| Anticancer activity of CD8 + T cells isolated from cancer-draining lymph nodes of the ES-ML/IFNtreated mice
We next examined the anticancer activity of CD8 + T cells in cancer-bearing mice treated with the ES-ML/IFN. Mice bearing intraperitoneal cancer were injected ip with β-ML and γ-ML twice from d 4. At d 11, we isolated CD8 + T cells from MLNs and PANs. PANs of untreated mice were small, and CD8 + T cells sufficient for this assay could not be prepared from PANs.
We co-cultured the isolated CD8 + T cells with Colon26/Luc cells for 3 d and measured the number of live Colon26/Luc cells by luminescence activity. Cancer cells were significantly decreased by coculture with CD8 + T cells isolated from the ES-ML/IFN-treated mice ( Figure S8A ). Conversely, CD8 + T cells isolated from untreated mice did not exhibit such activity.
| Activation of CD8 + T cells and NK cells in the cancer-bearing mice treated with the ES-ML/IFN
We evaluated the responsiveness of T cells from cancer-bearing mice to Colon26 cells. Spleen and MLN cells were isolated from mice bearing intraperitoneal Colon26/Luc cancer cells and treated ip twice with β-ML and γ-ML or untreated. Isolated cells were F I G U R E 5 Increased numbers of immune cells in the spleen and para-aortic lymph nodes (PANs) of cancer-bearing mice treated with the ES-ML/IFN. Mice with peritoneally disseminated Colon26 cells were treated with the ES-ML/IFN as described in Figure 4 or untreated (no therapy). The numbers of immune cells in the spleen and PANs of mice were counted at d 17. Data for the no therapy group are indicated by white bars, and those of the therapy group (n = 12) are indicated by black bars. The difference between values of no therapy and therapy groups was evaluated using Student's t test (*P < .05, **P < .01) co-cultured with Colon26/Luc, and production of IFN-γ by these cells was analyzed.
Whole spleen and MLN cells of untreated mice showed no or a very low response to the cancer cells ( Figure 6A ). Conversely, cells isolated from mice treated with β-ML and γ-ML secreted IFN-γ in response to Colon26 cells, indicating that T cells reactive to cancer cells were primed in the cancer-bearing mice by therapy with the ES-ML/IFN.
Colon26 cells produce a murine leukemia virus gp70-derived
and H2-L d -binding peptide AH-1. T cells isolated from the treated mice also reacted to this peptide, further indicating the induction of cancer antigen-specific activation of T cells following the therapy ( Figure 6A ). Purified CD8 + cells ( Figure 6B ), but not CD4 + cells (data not shown), secreted IFN-γ when co-cultured with Colon26 cells. The response of CD8 + T cells to BALB-MC, a mammary cancer cell line derived from the BALB/c strain, was much lower than that to Colon26 cells. Therefore, priming of CD8 + T cells by ES-ML/IFN therapy was specific to Colon26 cells ( Figure 6B ).
To compare β-ML and γ-ML for their activity to prime T cells, we injected cancer-bearing mice with either β-ML or γ-ML and examined the reactivity of MLNs cells. β-ML primed Colon26-reactive T cells much more effectively than did γ-ML ( Figure S8B ).
We also examined production of IFN-γ by NK cells of treated and untreated mice. NK cells from both groups did not produce IFN-γ when co-cultured with Colon26/Luc (data not shown). However, significantly higher numbers of NK cells derived from the treated mice produced IFN-γ upon co-culture with syngeneic SP2/0 cells, compared with those cells from untreated mice, indicating activation of NK cells following the ES-ML/IFN therapy ( Figure S9 ).
| Contribution of CD8 + T cells to therapeutic effect of the ES-ML/IFN
To examine the contribution of CD8 + T cells to therapeutic effect of the ES-ML/IFN, we conducted a depletion experiment with anti-CD8 monoclonal antibody.
We injected anti-CD8 monoclonal antibody ip at d −3, −1, and 6.
Colon26/Luc cells were injected ip at d 0 to establish the peritoneal dissemination model and treated with β-ML and γ-ML from d 4, twice a week for 2 wk. The therapeutic effect was significantly impaired by depletion of CD8 + T cells (Figure 7) . Conversely, the difference in cancer progression between CD4 + T cell-depleted and non-depleted mice was not statistically significant ( Figure S10 ).
| D ISCUSS I ON
We currently tested a strategy to use pluripotent stem cell-de- (Figures 1 and S1) . These effects were probably induced via the Jak-Stat intracellular signaling pathway. 8 It is known that p53 promotes apoptosis through extrinsic death receptor-mediated and intrinsic mitochondrial pathways. 35 p53 is activated functionally in response to diverse stress stimuli including activation of oncogenes, DNA damage, nutrient deprivation, or hypoxia. 36 Conversely, IFN-β is reported to enhance the expression of p53 protein, although IFN-β signaling itself does not activate p53. Therefore, p53 and IFN-β are important for the induction of apoptosis in cancer cells. 37 Based on these issues, stress stimuli may be involved in the direct anticancer effects of IFNs via the ES-ML/IFN in our system, especially under in vivo conditions. An in vivo study also clarified the therapeutic effect of the ES-ML/IFN including indirect potency. While sole treatment with γ-ML did not exhibit any therapeutic effect against Colon26 cancer in vivo ( Figure S4 ), β-ML did show manifest therapeutic effects (Figures 2   and 3 ). Indeed, their sensitizing efficacy for cancer cell-reactive CD8 + T cells was much more effective than that of γ-ML ( Figure S8B ). The immune-stimulating effect of β-ML on host cells was likely to be essential to elicit the therapeutic effect in our in vivo models, because the depletion of CD8 + T cells in the mice canceled the therapeutic effect of β-ML (Figure 7) . It is conceivable that the effective induction of cancer-specific cytotoxic T cells in the ES-ML/IFN-treated mice is mediated by host-derived antigen-presenting cells including dendritic cells and macrophages, which have been activated by type I interferons, because allogeneic ES-ML itself should function as a drug delivery system for interferons but not antigen-presenting cells in the tumor microenvironment.
In our preliminary results, the number of F4/80 + macrophages in cancer tissues tended to be increased by treatment with the ES-ML/ IFN (data not shown), although the difference between nontreated and treated groups was not statistically significant. Conversely, Considering clinical application of iPS cell-based anti-cell therapy, use of iPS cells originated from the patient to be treated is not practical. Generation of clinical grade iPS cells for individual patients is very expensive. In addition, generation of iPS cells and differentiation of these cells to produce therapeutic cells may take several months and miss the timing to treat cancer patients. Therefore, use of pre-established allogeneic iPS cell-derived cells may be necessary.
MHC-class I expression in cancer tissue
F I G U R E 7 Contribution of CD8 + T cells to the therapeutic effect of the ES-ML/IFN. An anti-CD8 antibody was administrated ip at d −3, −1, and 6 (50 μg/ injection/mouse). Colon26/Luc cells (1 × 10 6 cells/mouse) were injected ip on d 0, and mice were treated with the ES-ML/IFN as described in Figure 4 . Cancer growth was monitored by in vivo luminescence analysis from d 4. A, Imaging data of luciferase assay are shown. B, The presence of CD4 + and CD8 + T cells in peripheral blood was examined to confirm depletion of CD8 + T cells at d −1. C, Fold changes in luminescence counts of each mouse in comparison with counts observed on d 4. The difference between the two groups was statistically significant (**P < .01, linear mixed model)
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